Home Featured Page 8

Featured

Latest

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

March 2025’s Psychedelic Policy Momentum: New Bills Filed Across the U.S....

Vince Kadlubek – Meow Wolf & PORTAL

The Tide Is Turning: Psychedelic Therapies Take a Step Toward the...

Behind the Bill: Inside a Bipartisan Effort to Bring Psychedelic Therapy...

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD...

February 2025 Psychedelic Patent Update: Terran Secures New Overlapping IP; Porta...

Beyond Guinea Pigs: Ensuring Access to Psychedelic Therapies for Europeans

SoundMind Institute – Dr Hannah McLane

1...789...291 Page 8 of 291

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

March 2025’s Psychedelic Policy Momentum: New Bills Filed Across the U.S....

Vince Kadlubek – Meow Wolf & PORTAL

The Tide Is Turning: Psychedelic Therapies Take a Step Toward the...

Behind the Bill: Inside a Bipartisan Effort to Bring Psychedelic Therapy...

Fayzan Rab – Emory University

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD...

February 2025 Psychedelic Patent Update: Terran Secures New Overlapping IP; Porta...

Beyond Guinea Pigs: Ensuring Access to Psychedelic Therapies for Europeans

SoundMind Institute – Dr Hannah McLane

EDITOR PICKS

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY